We first examined the impact of Sorafenib and/or ASC‐J9® on the expression of p‐STAT3 and STAT3 in HCC HA22T cells, and results revealed that Sorafenib alone led to little decrease of p‐STAT3 (Y705), while ASC‐J9® suppressed p‐STAT3 (Y705) expression (Fig. 3e). The gene discussed is STAT3; the disease is hepatocellular carcinoma.